Drug Approval | November 08, 2025
Zydus Lifesciences secures FDA tentative approval for Olaparib tablets
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
The company is bringing precision therapies for gynaecological cancers
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
